Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1265)	3/10/1998 11:25:00 AM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 2173

'An effective glucose control drug should,ideally, drive insulin requirements down; not be overwhelmed by it.' Your statement presupposes that pramlintide is a glucose control protein. It can be argued that it may prove to be the essential companion protein - necessary for better controlling the long term effects of diabetes. I am neither a shareholder nor an expert but simply one who is waiting for a better treatment option for Type I diabetes - rate of incidence of Type I diabetes is growing at phenomenal rates according to Juvenile Diabetes Foundation.

To: Rudy Saucillo who wrote (1265)	3/10/1998 7:50:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Dear Rudy: As you only do it for fun and I am a shareholder since 1995, I think I must have read the Aug. news release many more times than you did. The 0.4% reduction of HbA1c is for type I patients with 8% or higher HbA1c entering the trial regardless the insulin dosage used. It is from 144 out of 221 patients, about 66% of the whole patient population. That is good enough for both US and European approval if confirmed by upcoming trials. As a matter of fact, I think the biggest mistake the company made was not for failing to control insulin dosage in last trial IIIs (sometimes you can not forecast everything), it was their decision to prolong the US type I trial to 12 months instead of 6 months. To get the drug to the market first and money coming to support further testing should have been their number one choice. It is too late for that now as the type I trial has been changed once and you can not change it again. At least the European file will be earlier now. D.Right